Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Blake

Showing results (101-110 of 141) with videos related to

Pageof 15
Sort By:
Journal of Medicinal Chemistry|January 20, 2006
Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-onesEli M Wallace, Joseph Lyssikatos, James F Blake, et al.
Bioorganic & Medicinal Chemistry Letters|May 19, 2009
Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitorsRobert T Hendricks, Jay B Fell, James F Blake, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2017
Low Hesperian <i>P</i><sub>CO2</sub> constrained from in situ mineralogical analysis at Gale Crater, MarsThomas F Bristow, Robert M Haberle, David F Blake, et al.
Physical Review Letters|July 25, 2015
Dichotomy between the Hole and Electron Behavior in Multiband Superconductor FeSe Probed by Ultrahigh Magnetic FieldsM D Watson, T Yamashita, S Kasahara, et al.
Journal of Medicinal Chemistry|April 17, 1998
(3R,4S)-3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]chroman-4,7-diol: a conformationally restricted analogue of the NR2B subtype-selective NMDA antagonist (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)- 1-propanolT W Butler, J F Blake, J Bordner, et al.
Physical Review Letters|December 5, 2015
Publisher's Note: Dichotomy between the Hole and Electron Behavior in Multiband Superconductor FeSe Probed by Ultrahigh Magnetic Fields [Phys. Rev. Lett. 115, 027006 (2015)]M D Watson, T Yamashita, S Kasahara, et al.
Bioorganic & Medicinal Chemistry Letters|March 12, 2011
Discovery and SAR of spirochromane Akt inhibitorsNicholas C Kallan, Keith L Spencer, James F Blake, et al.
Bioorganic & Medicinal Chemistry Letters|September 3, 2010
Discovery of pyrrolopyrimidine inhibitors of AktJames F Blake, Nicholas C Kallan, Dengming Xiao, et al.
Journal of Medicinal Chemistry|January 21, 2015
Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2Li Ren, Jonas Grina, David Moreno, et al.
JCO Precision Oncology|September 14, 2020
Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered CancerLori J Wirth, Takashi Kohno, Hibiki Udagawa, et al.
Pageof 15

Showing results (101-110 of 141) with videos related to

Sort By:
Pageof 15
Journal of Medicinal Chemistry|January 20, 2006
Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-onesEli M Wallace, Joseph Lyssikatos, James F Blake, et al.
Bioorganic & Medicinal Chemistry Letters|May 19, 2009
Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitorsRobert T Hendricks, Jay B Fell, James F Blake, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2017
Low Hesperian <i>P</i><sub>CO2</sub> constrained from in situ mineralogical analysis at Gale Crater, MarsThomas F Bristow, Robert M Haberle, David F Blake, et al.
Physical Review Letters|July 25, 2015
Dichotomy between the Hole and Electron Behavior in Multiband Superconductor FeSe Probed by Ultrahigh Magnetic FieldsM D Watson, T Yamashita, S Kasahara, et al.
Journal of Medicinal Chemistry|April 17, 1998
(3R,4S)-3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]chroman-4,7-diol: a conformationally restricted analogue of the NR2B subtype-selective NMDA antagonist (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)- 1-propanolT W Butler, J F Blake, J Bordner, et al.
Physical Review Letters|December 5, 2015
Publisher's Note: Dichotomy between the Hole and Electron Behavior in Multiband Superconductor FeSe Probed by Ultrahigh Magnetic Fields [Phys. Rev. Lett. 115, 027006 (2015)]M D Watson, T Yamashita, S Kasahara, et al.
Bioorganic & Medicinal Chemistry Letters|March 12, 2011
Discovery and SAR of spirochromane Akt inhibitorsNicholas C Kallan, Keith L Spencer, James F Blake, et al.
Bioorganic & Medicinal Chemistry Letters|September 3, 2010
Discovery of pyrrolopyrimidine inhibitors of AktJames F Blake, Nicholas C Kallan, Dengming Xiao, et al.
Journal of Medicinal Chemistry|January 21, 2015
Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2Li Ren, Jonas Grina, David Moreno, et al.
JCO Precision Oncology|September 14, 2020
Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered CancerLori J Wirth, Takashi Kohno, Hibiki Udagawa, et al.
Pageof 15